shareholder votes by their feet., page-7

The Nasdaq listing should have been done last year following the BARDA grant. But the initiative was postponed to September and Biota will be delisted on ASX at the same time.

What on earth are they thinking of?

If Biota had been dual listed following the BARDA grant, the last Japan flu season and the success of Phase IIb trial for Vapendavir would be able to push up BTA share price in the US. Then, the 26% of Biota should not be sold for 80c each share.


I think the lower the share price, the more objection the merger proposal will get.

Any other failure of Biota management's strategic move? We will see soon.